Stocktoria
Keros Therapeutics, Inc. KROS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-08
Keros Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 | $20.1M |
| R&D expense | $129.6M | $173.6M | $135.3M | $87.3M | $55.1M |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M |
| Income tax | $4.9M | $300,000 | $0 | $0 | $2.0M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M |
| EPS (diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M |
| Cash & equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M |
| Shareholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M |
Source: SEC EDGAR filings · CIK 0001664710 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.